DV
Dividend Vision

MXCT — MaxCyte Inc

MaxCyte Inc (MXCT)

Total return is -92.2% over the past 5 years, 181.6 points behind SPY at 89.4%. Its deepest 1-year drawdown was 63.1%.

MaxCyte Inc is a life sciences company that discovers, develops, and commercializes cell therapeutics through electroporation technology and instruments, including its ExPERT product line for cell transfection and engineering at various scales, along with related consumables and disposable processing assemblies sold to pharmaceutical, biotechnology, and cell therapy developers. The company does not currently distribute dividends. MaxCyte appeals to growth-oriented investors interested in biotechnology and cell therapy development rather than income investors.

MXCT key facts

Asset type
Stock
Asset class
Equity
Inception date
07/30/2021
Last close
$1.32
Market cap
$125,332,352
Average volume
1001100.0
Beta
1.663
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.36